Showing results (61-70 of 155) with videos related to
Sort By:
Pageof 16
International Journal of Molecular Sciences|May 25, 2024
Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6DAdrián Sanvicente García, Manuel Pedregal, Lucía Paniagua-Herranz, et al.Cancer Chemotherapy and Pharmacology|October 7, 2016
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover studyWijith Munasinghe, Sven Stodtmann, Anthony Tolcher, et al.Journal for Immunotherapy of Cancer|January 20, 2024
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumorsMarkus Joerger, Emiliano Calvo, Heinz Laubli, et al.Journal of Hematology & Oncology|December 13, 2023
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learnedAlfonso López de Sá, Cristina Díaz-Tejeiro, Elisa Poyatos-Racionero, et al.International Journal of Molecular Sciences|December 17, 2024
Understanding the Preclinical Efficacy of Antibody-Drug ConjugatesCristina Díaz-Tejeiro, Alfonso López de Sá, Elisa Poyatos-Racionero, et al.BJU International|July 13, 2020
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)Alejo Rodriguez-Vida, Aristotelis Bamias, Emilio Esteban, et al.Oncology|October 17, 2002
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot studyEmiliano Calvo, Javier Cortés, María González-Cao, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 6, 2021
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I studyRebecca Kristeleit, Victor Moreno, Valentina Boni, et al.British Journal of Cancer|February 16, 2023
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumoursJayesh Desai, Peter Fong, Victor Moreno, et al.The Oncologist|June 2, 2018
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)Hendrik-Tobias Arkenau, Juan Martin-Liberal, Emiliano Calvo, et al.Pageof 16